Pharmacyclics, Inc. (NASDAQ:PCYC)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.

Recs

0
Player Avatar bIlluminati (30.14) Submitted: 4/10/2012 1:38:35 PM : Underperform Start Price: $25.74 PCYC Score: -110.86

Another pharma company in development with long road before profitability.

Featured Broker Partners


Advertisement